Covered recipient · General Payments record
NABEEL NAZIR
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2023–2024
$374.71
- Reported across 17 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $342.44 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $80.60 | 3 |
| Novo Nordisk AS | $73.72 | 4 |
| DEXCOM, INC. | $46.25 | 2 |
| PFIZER INC. | $42.17 | 2 |
| Currax Pharmaceuticals LLC | $33.34 | 2 |
| Dynavax Technologies Corporation | $23.42 | 1 |
| Gilead Sciences, Inc. | $21.58 | 1 |
| Exact Sciences Corporation | $21.36 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Currax Pharmaceuticals LLC | $17.70 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089513758 | CMS |
| Currax Pharmaceuticals LLC | $15.64 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089513760 | CMS |
| Dexcom, Inc. | $22.28 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153324415 | CMS |
| Dexcom, Inc. | $23.97 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153324417 | CMS |
| Dynavax Technologies Corporation | $23.42 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1082152159 | CMS |
| Exact Sciences Corporation | $21.36 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114806075 | CMS |
| Gilead Sciences, Inc. | $21.58 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133635477 | CMS |
| Lilly USA, LLC | $23.73 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135265916 | CMS |
| Lilly USA, LLC | $32.08 | 06/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135265920 | CMS |
| Lilly USA, LLC | $24.79 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135230779 | CMS |
| Novo Nordisk Inc | $16.03 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096649315 | CMS |
| Novo Nordisk Inc | $18.92 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097466488 | CMS |
| Novo Nordisk Inc | $18.92 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096647220 | CMS |
| Novo Nordisk Inc | $19.85 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097087775 | CMS |
| PFIZER INC. | $26.50 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131806411 | CMS |
| PFIZER INC. | $15.67 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131832920 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2023, 2024
- Source files
- Dataset page · Bulk file · PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.